Retatrutide: Spark Notes Guide
What It Is (One Sentence)
A once-weekly injectable from Eli Lilly that activates three hormone receptors (GLP-1 + GIP + Glucagon) to produce ~25-29% weight loss—the most powerful obesity drug in development.
The Triple Mechanism
| Receptor | What It Does | Drugs That Use It |
|---|---|---|
| GLP-1 | Kills appetite, slows digestion, improves blood sugar | Ozempic, Wegovy |
| GIP | Amplifies GLP-1 effects, improves nutrient handling | Added in Mounjaro/Zepbound |
| Glucagon | Increases metabolism, burns liver fat | Only in Retatrutide |
The glucagon component is the differentiator—it makes you burn more calories (not just eat less) and has dramatic effects on liver fat.
Key Numbers
| Metric | Result |
|---|---|
| Weight loss (Phase 3, 68 weeks) | 28.7% (~71 lbs from 249 lb baseline) |
| Liver fat reduction | 82-86% |
| Fatty liver resolution | 93% achieved normal liver fat |
| Prediabetes → Normal | 72% reverted to normoglycemia |
| HbA1c reduction (diabetics) | Up to 2.0% |
| LDL cholesterol reduction | ~20% |
| Blood pressure reduction | ~14 mmHg systolic |
Side Effects
Common (GI): Nausea (38-43%), diarrhea (33%), vomiting (21%), constipation (22-25%)
- Mostly during dose escalation
- Improve over time
New Signal: Dysesthesia (tingling/altered skin sensation)
- 9% at 9mg, 21% at 12mg
- Usually mild, rarely causes discontinuation
Discontinuation rates: 12-18% (higher than existing GLP-1s)
Alcohol/Addiction Effects
GLP-1 drugs (including retatrutide) reduce cravings by blunting dopamine release in the brain's reward centers (VTA, nucleus accumbens). Studies show ~68% reduction in alcohol intake among heavy drinkers. Many users report simply "forgetting" to drink or losing interest entirely.
Status
- Now: Phase 3 trials (TRIUMPH program)
- First Phase 3 results: December 2025 ✓ (TRIUMPH-4 successful)
- Remaining trials: 7 more readouts expected 2026
- Expected approval: 2026-2027
Conservative Dosing Protocol
Clinical trials use aggressive 4-week escalation starting at 2mg. This approach is more conservative to minimize side effects:
| Week | Dose | Notes |
|---|---|---|
| 1-2 | 0.5 mg | Sub-therapeutic introduction |
| 3-4 | 1.0 mg | Build tolerance |
| 5-6 | 1.0 mg | Hold to confirm tolerance |
| 7-8 | 1.5 mg | First meaningful therapeutic dose |
| 9-10 | 1.5 mg | Hold and assess response |
| 11-12 | 2.0 mg | Low therapeutic range (optional) |
| 13+ | Hold | Reassess every 4-6 weeks |
Key principles:
- Slower = fewer GI sides. Trial data showed extended escalation significantly reduced nausea/vomiting
- You may not need high doses. 12mg is for maximizing weight loss in severely obese populations; 2-4mg may be sufficient
- Hold at any dose if sides are problematic before advancing
- Protein stays high (1g per lb target bodyweight)—these drugs can accelerate lean mass loss if protein is inadequate
- Training intensity stays up—the stimulus to retain muscle is non-negotiable
When to consider advancing:
- Weight loss stalls for 3+ weeks
- Appetite suppression diminishes noticeably
- No meaningful side effects at current dose